License Revenue (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2020
License Revenue (Details) [Line Items]
Upfront license Payment	$ 6.0				$ 6.0
Milestone license payments			$ 6.0	$ 14.0
Net of withholding taxes and other fees and royalties	$ 4.5		$ 4.5
Description of licensing agreement	It is expected that the Company will supply lenzilumab to the Licensee for a minimum of 7.5 years at a cost-plus basis from an existing or future manufacturer.
license revenue	$ 0.8
License revenue	0.2	$ 1.0
First Milestone [Member]
License Revenue (Details) [Line Items]
Milestone license payments	6.0
Net of withholding taxes and other fees and royalties	4.5
South Korea Agreement [Member]
License Revenue (Details) [Line Items]
license revenue	$ 2.4